The constitutive activation of the NF-κB and BCR pathways has been suggested to be required for the anti-apoptotic phenotype and chemotherapy-resistance in ABC-DLBCL [35, 109, 163]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.